A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

Inclusion Criteria:

• Participant has provided written informed consent and agrees to comply with thestudy protocol.

• Participant with PBC diagnosis.

• Participant naïve to elafibranor, for whom the treating physician has decided tostart treatment with elafibranor.

• If a participant has a caregiver who agrees to complete the caregiverquestionnaires, an informed consent should be collected from the caregiver beforeany data is collected.

Exclusion Criteria:

• Participant who started elafibranor treatment before baseline visit.

• Participant is currently participating in, plans to participate in or hasparticipated in an investigational drug study or medical device study containingactive substance within 30 days or five half-lives of the drug/active substance,whichever is longer, prior to baseline visit.

• Participant with known hypersensitivity to the product or to any of its excipients.

• Participant with mental instability or incompetence, such that the validity ofinformed consent or ability to be compliant with the study is uncertain.